Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBITDA: 2015-2024

Historic EBITDA for Anaptysbio (ANAB) over the last 10 years, with Dec 2024 value amounting to -$144.1 million.

  • Anaptysbio's EBITDA rose 147.88% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 47.50%. This contributed to the annual value of -$144.1 million for FY2024, which is 9.45% up from last year.
  • As of FY2024, Anaptysbio's EBITDA stood at -$144.1 million, which was up 9.45% from -$159.2 million recorded in FY2023.
  • Over the past 5 years, Anaptysbio's EBITDA peaked at -$20.3 million during FY2020, and registered a low of -$159.2 million during FY2023.
  • For the 3-year period, Anaptysbio's EBITDA averaged around -$145.6 million, with its median value being -$144.1 million (2024).
  • Per our database at Business Quant, Anaptysbio's EBITDA spiked by 79.05% in 2020 and then slumped by 187.15% in 2021.
  • Anaptysbio's EBITDA (Yearly) stood at -$20.3 million in 2020, then crashed by 187.15% to -$58.2 million in 2021, then plummeted by 129.41% to -$133.5 million in 2022, then decreased by 19.19% to -$159.2 million in 2023, then climbed by 9.45% to -$144.1 million in 2024.